Form 4: Insmed Inc. Officer Sells Shares to Cover Tax Obligations After PSU Vesting
SEC Form 4 Filing
Martina Flammer, Chief Medical Officer of Insmed Inc., reports the acquisition of shares through vested Performance Stock Units (PSUs) and subsequent sale of shares to cover tax obligations.
Summary
- On February 5, 2025, Martina Flammer, Chief Medical Officer of Insmed Inc., acquired 70,943 shares of common stock upon the vesting of Performance Stock Units (PSUs) granted on January 6, 2022.
- These PSUs vested due to the achievement of applicable performance and service conditions.
- On February 6 and 7, 2025, Flammer sold 33,055 and 60 shares of common stock, respectively, to satisfy tax withholding obligations and cover broker fees.
- The sale on February 6 occurred at a weighted average price of $80.9 per share, with prices ranging from $80.57 to $81.43.
- The sale on February 7 occurred at a price of $79.59 per share.
- Following these transactions, Flammer directly owns 137,993 shares of Insmed Inc. common stock.
Sentiment
Score: 5
Explanation: The document reflects standard insider trading activity related to stock-based compensation, with no particularly positive or negative implications.
Industry Context
This Form 4 filing is a routine disclosure of stock transactions by a company insider, which is common in the pharmaceutical industry as part of executive compensation packages.
Comparison to Industry Standards
- Executive compensation packages often include stock options and restricted stock units (RSUs) or PSUs that vest over time, similar to the PSUs granted to Martina Flammer.
- Sales of shares to cover tax obligations upon vesting are a standard practice among executives in publicly traded companies.
- Companies like Amgen, Gilead Sciences, and Biogen also have similar executive compensation structures that involve stock-based awards and subsequent sales for tax purposes.
Stakeholder Impact
- The sale of shares by an officer could have a minor impact on shareholder sentiment, but is unlikely to be significant given the context of tax obligations.
Key Dates
| Date | Description |
|---|---|
| January 6, 2022 | Date Performance Stock Units (PSUs) were originally granted. |
| February 5, 2025 | Date of PSU vesting and acquisition of 70,943 shares. |
| February 6, 2025 | Date of sale of 33,055 shares at a weighted average price of $80.9 per share. |
| February 7, 2025 | Date of sale of 60 shares at $79.59 per share. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.